Primary Hyperoxaluria Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Primary Hyperoxaluria remains an active clinical development field. Development is moving beyond single surrogate measures toward integrated cardiometabolic, renal and clinical-outcome evidence, with convenience and persistence becoming major differentiators. The PatSnap evidence set used here contains 18 matched trial records and 41 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| CTR20262510 | YOLT-203 | Phase 1; 进行中 （尚未招募） | Yoltech Therapeutics Co., Ltd. | China | (试验全程) | Timing not listed |
| NCT07587021 | YOLT-203 | Phase 2; Not yet recruiting | Yoltech Therapeutics Co., Ltd. | Geography not listed | Percent Change From Baseline in 24-Hour Urinary Oxalate (BSA-Corrected) (Months 2 to 6) | 2027-08-01 |
| NCT06892301 | YOLT-203 | Early Phase 1; Active, not recruiting | Guangzhou Women & Childrens Medical Center | China | Incidence of Treatment-Emergent Adverse events (through week 52) | 2026-07-01 |
| NCT06839235 | ABO-101 (Arbor Biotechnologies) | Phase 1/2; Recruiting | Arbor Biotechnologies, Inc. | United States, United Kingdom, France, Tunisia, Germany | Incidence and severity of treatment-emergent adverse events (TEAEs), including ABO-101-related TEAEs and serious adverse events (SAEs) (Up to 6 months) | 2029-03-01 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- A Phase 2 Open-Label Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nedosiran in Pediatric Patients From Birth to 11Years of Age With Primary Hyperoxaluria and Relatively Intact Renal Function (Phase 2): the indexed record reports PH1(Mean) = -68.34 Percent change (Standard Deviation, 8.574); PH1(Mean) = -74.06 Percent change (Standard Deviation, 13.193); -.
- Final 60-Month Efficacy, Safety, and Kidney Stone Outcomes of a Phase 3 Trial of Lumasiran for Primary Hyperoxaluria Type 1 in Infants and Young Children (Phase 3): the indexed record reports NC grade = 86.0 %.
- Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-up of the Phase 3 ILLUMINATE-C Trial (Phase 3): the indexed record reports POx level(24-month) = -30.6 %; POx level(24-month) = -60.5 %.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including YOLT-203 (Phase 2; GOX), ABO-101 (Arbor Biotechnologies) (Phase 1/2; GOX). Company & Deal Intelligence records identify sponsor context for Yoltech Therapeutics Co., Ltd., Guangzhou Women & Childrens Medical Center, Arbor Biotechnologies, Inc.. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Active-comparator trials on top of contemporary standard of care.
- Hard cardiovascular, kidney or liver outcomes linked to earlier biomarker change.
- Evidence in underrepresented populations and patients with multiple comorbidities.
- Durability, adherence and post-discontinuation outcomes.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Primary Hyperoxaluria has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
